

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

SIGA TECHNOLOGIES INC
Form 8-K
July 10, 2003

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2003

SIGA Technologies, Inc.

Delaware
(State or other jurisdiction
of incorporation)

0-23047
Commission File Number

13-3864870
IRS Employer ID No.

420 Lexington Avenue, New York, New York 10170
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (212) 672-9100

SIGA TECHNOLOGIES, INC.

Form 8-K

TABLE OF CONTENTS

	Page
Item 5. Other Events	3
Item 7. Pro Forma Financial Statements and Exhibits	4
Signatures	5

- 2 -

Item 5. Other Events

On May 14, 2003, SIGA Technologies, Inc. (the "Company") signed definitive agreements to acquire substantially all of the assets of Plexus Vaccine Inc. and assume certain liabilities in exchange for 1,950,000 shares of the Company's common stock (par value \$.0001 per share) and 190,950 of the Company's warrants and options at an initial exercise price of \$1.62 per share. The acquisition was completed on May 23, 2003.

On June 20, 2003 the Company received gross proceeds of \$1,500,000 from a private placement of 1,250,000 shares of its common stock (par value \$.0001) and 625,000 warrants to purchase common stock at an initial exercise price of \$2.00 per share. The net proceeds from the private placement were \$1,350,000.

Statements contained herein and in future filings by the Company with the Securities and Exchange Commission, in the Company's press releases, and in oral

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

statements made by, or with the approval of, authorized personnel that relate to the Company's future performance, including, without limitation, statements with respect to the Company's anticipated results of operations or level of business for 2003 or for any other future period, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of the Company's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to the Company or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that the Company or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials.

More detailed information about the Company and the factors discussed above is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2002, and in other documents that the Company has filed with the Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.gov. Those documents may also be obtained free of charge from the Company. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

- 3 -

Item 7(a). Pro Forma Financial Statements and Exhibits

(b) Unaudited Pro Forma Balance Sheet (as of May 31, 2003)

The following unaudited pro forma balance sheet is provided for illustrative purposes only. It illustrates the Company's acquisition of substantially all the assets of Plexus Vaccine Inc. and the assumption of certain liabilities in exchange for 1,950,000 shares of the Company's common stock (par value \$.0001) and 190,950 of the Company's options and warrants at an initial exercise price of \$1.62 per share. It also illustrates the sale by the Company of 1,250,000 shares of its common stock for net proceeds of \$1,350,000, as described in Item 5 of this Form 8-K, as if the asset acquisition and private placement occurred on May 31, 2003. It does not purport to represent what the actual results of operations or financial position currently are as a result of the asset acquisition and private placement or otherwise, and is not necessarily indicative of the Company's future operating results.

	31-May-03	Adjustments	Adjusted as of 31-May-03
ASSETS			
Current Assets			
Cash & Cash Equiv	\$ 729,273	\$1,350,000	\$2,079,273
Accts. Receivable	78,335	--	78,335
Prepaid Expense	136,402	--	136,402
Total Current Assets	944,010	1,350,000	2,294,010
Fixed Assets			
Prop. Plant & Equipment-net	457,600	27,711	485,311

Edgar Filing: SIGA TECHNOLOGIES INC - Form 8-K

Other Assets	168,386	4,416,304	4,584,690
TOTAL ASSETS	\$1,569,996	\$5,794,015	\$7,364,011
LIABILITIES & EQUITY			
Current Liabilities			
Accounts Payable	\$ 578,446	\$ --	\$ 578,446
Accrued Expenses	112,416	729,142	841,558
Preferred Dividends Payable	7,520	--	7,520
Deferred Revenue	25,996	--	25,996
Total Current Liabilities	724,378	729,142	1,453,520
Equity			
Net Equity	\$ 845,618	\$5,064,873	\$5,910,491
TOTAL LIABILITIES & EQUITY	\$1,569,996	\$5,794,015	\$7,364,011

- 4 -

(c) Exhibits. The following documents are filed as exhibits to this report:

Exhibit	Description of Exhibit
99.1	Press Release, dated May 15, 2003, announcing the signing of definitive agreements in connection with the Company's purchase of substantially all the assets of Plexus Vaccine Inc.
99.2	Press Release, dated June 24, 2003, announcing the consummation of a private placement for 1,250,000 shares of the Company's common stock and warrants to purchase 625,000 shares of the Company's common stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has fully caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGA TECHNOLOGIES, INC.
(Registrant)

Date: July 10, 2003

By: /s/ Thomas N. Konatich

Thomas N. Konatich
Chief Financial Officer
(Principal Accounting Officer and
Financial Officer and Vice
President, Finance)

